Clinical Trials

Inclusion Criteria: 

All Cohorts

• Willingness and ability to complete surveys.
• English-speaking.

Cohort 1 (NTM-WATCH) additional criteria

• First positive sputum or bronchoalveolar lavage AFB culture for M. avium complex or M. abscessus within the prior 4 months.

Cohort 2 (NTM-TREAT) additional criteria Inclusion

• Meet ATS/IDSA disease criteria for M. avium complex or M. abscessus pulmonary disease10 , including the following:
  • At least 2 sputum or 1 bronchoalveolar lavage AFB culture positive for M. avium complex or M. abscessus;
  • Respiratory symptoms;
  • Nodular-bronchiectatic or cavitary disease on CT scan within prior 6 months.
• Initiating ATS/IDSA guideline-based anti-mycobacterial therapy for NTM pulmonary disease Inclusion • Within 3 months of treatment stop, after at least 6 months of guideline-based anti-mycobacterial therapy for MAC or MAB pulmonary disease.

Cohort 3 (NTM-TRACK) additional criteria

• Within 3 months of treatment stop, after at least 6 months of guideline-based anti-mycobacterial therapy for MAC or MAB pulmonary disease.

Exclusion Criteria:

All Cohorts

•  Cystic fibrosis, not on modulator therapy for at least 3 months prior to enrollment.

Cohort 1 (NTM-WATCH) additional criteria

• No prior history of positive AFB respiratory culture with the same species.
• Plan to start treatment for MAC or MAB pulmonary disease.

Cohort 2 (NTM-TREAT) additional criteria Inclusion

• More than 4 weeks of anti-mycobacterial therapy during the prior 2 years.

Cohort 3 (NTM-TRACK) additional criteria

• No additional exclusions.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/28/23. Questions regarding updates should be directed to the study team contact.